CSIMC Expert Member Yoshiaki Kamoya (Executive Officer, Shionogi) Says Price Cuts for Long-Listed Drugs and Perpetuation of Premium for New Drug Development Should Be Discussed Together

Yoshiaki Kamoya, Expert Member at CSIMC Last year, the Central Social Insurance Medical Council (CSIMC) approved an interim report that proposes a new rule that would reduce the NHI prices of long-listed drugs, or off-patent original drugs, if their generic...read more